Patents by Inventor Jorg-Christian Heinrich

Jorg-Christian Heinrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with thymine skeleton for use in medicine
    Patent number: 11214564
    Abstract: The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 4, 2022
    Assignee: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Michael Schroeder, Yixin Zhang, Jörg-Christian Heinrich, Joachim Haupt, Petra Lennig
  • NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
    Publication number: 20210130328
    Abstract: The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.
    Type: Application
    Filed: November 3, 2020
    Publication date: May 6, 2021
    Applicant: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Michael SCHROEDER, Yixin ZHANG, Jörg-Christian HEINRICH, Joachim HAUPT, Petra LENNIG
  • Uracil derivatives and use thereof
    Patent number: 9181199
    Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: November 10, 2015
    Assignee: RESprotect GmbH
    Inventors: Rudolf Fahrig, Kurt Eger, Martin Fuhrer, Nicole Heinze, Matthias Klemm, Jorg-Christian Heinrich
  • Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy
    Patent number: 8492537
    Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytotstatic treatment of a cancer patient.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: July 23, 2013
    Assignee: RESprotect GmbH
    Inventors: Rudolf Fahrig, Dieter Lohmann, Andreas Rolfs, Henrik Dieks, Janek Teubner, Jorg-Christian Heinrich
  • URACIL DERIVATIVES AND USE THEREOF
    Publication number: 20110166096
    Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.
    Type: Application
    Filed: June 25, 2009
    Publication date: July 7, 2011
    Applicant: RESPROTECT GMBH
    Inventors: Rudolf Fahrig, Kurt Eger, Martin Führer, Nicole Heinze, Matthias Klemm, Jörg-Christian Heinrich
  • NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY
    Publication number: 20100227834
    Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 9, 2010
    Applicant: RESprotech GmbH
    Inventors: Rudolf Fahrig, Dieter Lohmann, Andreas Rolfs, Henrik Dieks, Janek Teubner, Jörg-Christian Heinrich